Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) Invested Capital (2016 - 2025)

Sangamo Therapeutics has reported Invested Capital over the past 16 years, most recently at -$14.3 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 162.66% year-over-year to -$14.3 million; the TTM value through Dec 2025 reached -$14.3 million, down 162.66%, while the annual FY2025 figure was -$14.3 million, 162.66% down from the prior year.
  • Invested Capital for Q4 2025 was -$14.3 million at Sangamo Therapeutics, down from $6.2 million in the prior quarter.
  • Over five years, Invested Capital peaked at $469.4 million in Q1 2021 and troughed at -$14.3 million in Q4 2025.
  • A 5-year average of $194.9 million and a median of $184.3 million in 2023 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: rose 19.02% in 2021 and later crashed 162.66% in 2025.
  • Year by year, Invested Capital stood at $375.3 million in 2021, then decreased by 21.42% to $295.0 million in 2022, then crashed by 71.9% to $82.9 million in 2023, then tumbled by 72.53% to $22.8 million in 2024, then crashed by 162.66% to -$14.3 million in 2025.
  • Business Quant data shows Invested Capital for SGMO at -$14.3 million in Q4 2025, $6.2 million in Q3 2025, and $19.6 million in Q2 2025.